TherapeuticsMD TXMD
NASDAQ TXMD
$1.74 +0.06 (+3.57%)
At close: Nov 10, 2026 · 4:00 PM EST

TherapeuticsMD (TXMD) EV to CFO (2022 - 2026)

Updated

TherapeuticsMD's EV to CFO was 8.26 in Q2 2026, up 15.2% from 7.17 a year earlier but down 4.7% from the prior quarter.

Analysis

TherapeuticsMD (TXMD) EV to CFO (2022 - 2026) Analysis & Trends

For FY2025, EV to CFO at TherapeuticsMD came in at 7.69, up 85.1% from FY2024.

  • In earlier years, EV to CFO was 4.15 in FY2024 and 0.40 in FY2022.
  • Quarterly EV to CFO has moved between 0.40 (Q4 2022) and 8.66 (Q1 2026) over five years.
  • Compared with a year earlier, EV to CFO has increased for three straight quarters.
  • Per Business Quant data, TXMD's EV to CFO in the three quarters before Q2 2026 was 8.66 (Q1 2026), 7.69 (Q4 2025) and 2.57 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 TherapeuticsMD 20.14 Mn -12.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.29
Mar 31, 2026 5.54
Dec 31, 2025 4.64
Sep 30, 2025 2.57
Jun 30, 2025 7.17
Mar 31, 2025 2.39
Dec 31, 2024 4.15
Sep 30, 2023 1.80
Jun 30, 2023 0.83
Mar 31, 2023 1.00
Dec 31, 2022 0.26
Sep 30, 2022 0.85
API Access

TherapeuticsMD EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=TXMD&period=max&api_key=YOUR_API_KEY